
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences Inc. is advancing its clinical-stage product candidates, exemplified by the promising prospects for darovasertib in combination with crizotinib, which management believes could have a hazard ratio (HR) of 0.6 or lower, leading to swift market uptake. The company's ongoing enthusiasm for its product pipeline, particularly the combinations of its PARG inhibitor IDE161 with IDE849 and other antibody-drug conjugates (ADCs), positions it favorably for future developments and potential approvals. Management's confidence in upcoming studies, including a registrational study in small cell lung cancer (SCLC) and the rapid enrollment of participants, underscores the robust clinical activity anticipated from their precision medicine strategies.
Bears say
IDEAYA Biosciences reported a net loss of $83.3 million, or $0.94 per share, which was slightly better than the projected loss of $1.05 per share, primarily due to collaboration revenue from Servier. The company faces significant risks related to research and development, regulatory approvals, and potential commercial challenges, particularly with its key product candidates darovasertib, IDE397, and IDE849, which may not achieve sales estimates or could encounter competition from emerging therapies. Additionally, the possibility of dilutive financing further exacerbates concerns regarding the company's financial health and market outlook.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares